New guideline urges earlier screening for cardiovascular-kidney-metabolic syndrome

A new national guideline is trying to catch a dangerous cluster of risks before it turns into diabetes, kidney failure or heart disease. The American Heart Association and the American College of Cardiology, with help from the American Diabetes Association and the American Society of Nephrology, issued the first comprehensive clinical practice guideline for cardiovascular-kidney-metabolic syndrome on June 9, 2026.

The guidance reframes excess body fat, blood sugar problems, kidney disease and cardiovascular risk as one linked syndrome that should be staged and tracked in routine care. It replaces and expands the 2013 obesity guideline, signaling a shift from treating weight alone to looking for the full chain of warning signs that often develop together.

The guideline recommends CKM staging for youths and adults, from stage 0 through stage 4. Stage 1 includes excess or dysfunctional adiposity. Stage 2 includes metabolic risk factors or moderate-to-high-risk chronic kidney disease. Higher stages are tied to greater burdens of type 2 diabetes, chronic kidney disease, cardiovascular disease and mortality.

That staging approach could change how primary care works day to day. Instead of waiting for a patient to arrive with a heart event, advanced kidney damage or long-standing diabetes, clinicians are being pushed to identify people earlier, estimate absolute risk and choose treatment before the syndrome progresses. The American Heart Association says the goal is to reduce cardiovascular events and loss of kidney function across the life course while also encouraging stage regression through lifestyle changes and weight loss.

The warning signs are widespread. The American Heart Association says nearly 90% of U.S. adults have at least one CKM risk factor, and its implementation materials say about 1 in 3 adults have at least three. The organization also says at least 3 out of 4 adults may have reversible CKM syndrome, underscoring how many patients could benefit from earlier detection and coordinated treatment.

The risk factors include excess weight, high blood pressure, abnormal lipids, high blood glucose or prediabetes, reduced kidney function and diabetes. The AHA has described CKM syndrome as a major public health threat because the disease burdens rise together and care is often fragmented across separate specialties. Chiadi E. Ndumele, who chaired the writing committee, called it a “real, rising public health threat.”

The latest guideline builds on a 2023 American Heart Association presidential advisory that first defined CKM syndrome and called for clearer staging, better prediction tools and more coordinated, interdisciplinary care. The association launched a CKM Health Initiative in 2024, and the new guidance is meant to move that effort into routine practice, where earlier screening could change outcomes long before severe disease sets in.